{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:36:19Z","timestamp":1791916579769,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10792-021-01805-1","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T04:03:08Z","timestamp":1615953788000},"page":"2495-2504","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Intravitreal rituximab monotherapy for management of eyes with vitreoretinal lymphoma: initial experience from India"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5615-7734","authenticated-orcid":false,"given":"Pukhraj","family":"Rishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep T.","family":"Manchegowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshal P.","family":"Gondhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekta","family":"Rishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpita","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanian","family":"Krishnakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirumalairaj","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotirmay","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"issue":"5","key":"1805_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.survophthal.2013.12.001","volume":"59","author":"MS Sagoo","year":"2014","unstructured":"Sagoo MS, Mehta H, Swampillai AJ, Cohen VM et al (2014) Primary intraocular lymphoma. Surv Ophthalmol 59(5):503\u2013516","journal-title":"Surv Ophthalmol"},{"issue":"9","key":"1805_CR2","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/S0161-6420(99)90341-X","volume":"106","author":"EK Akpek","year":"1999","unstructured":"Akpek EK, Ahmed I, Hochberg FH et al (1999) Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmol 106(9):1805\u20131810","journal-title":"Ophthalmol"},{"key":"1805_CR3","first-page":"564","volume":"36","author":"SE Coupland","year":"2008","unstructured":"Coupland SE, Damato B (2008) Underst intraocular lymphomas Clin Exp Ophthalmol 36:564\u2013578","journal-title":"Underst intraocular lymphomas Clin Exp Ophthalmol"},{"key":"1805_CR4","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/archopht.1997.01100160322009","volume":"115","author":"BC Fishburne","year":"1997","unstructured":"Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA (1997) Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 115:1152\u20131156","journal-title":"Arch Ophthalmol"},{"key":"1805_CR5","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S0161-6420(02)01125-9","volume":"109","author":"JR Smith","year":"2002","unstructured":"Smith JR, Rosenbaum JT, Wilson DJ et al (2002) Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmol 109:1709\u20131716","journal-title":"Ophthalmol"},{"key":"1805_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/bjo.2007.127928","volume":"92","author":"S Frenkel","year":"2008","unstructured":"Frenkel S, Hendler K, Siegal T et al (2008) Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol 92:383\u2013388","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"1805_CR7","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/sj.eye.6702804","volume":"21","author":"AS Kitzmann","year":"2007","unstructured":"Kitzmann AS, Pulido JS, Mohney BG et al (2007) Intraocular use of rituximab. Eye 21(12):1524\u20131527","journal-title":"Eye"},{"issue":"7","key":"1805_CR8","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1001\/archopht.126.7.1002","volume":"126","author":"N Ohguro","year":"2008","unstructured":"Ohguro N, Hashida N, Tano Y (2008) Effect of intravitreal rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma. Arch Ophthalmol 126(7):1002\u20131003","journal-title":"Arch Ophthalmol"},{"key":"1805_CR9","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJ et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034\u20135043","journal-title":"J Clin Oncol"},{"issue":"3","key":"1805_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/tvst.1.3.1","volume":"1","author":"N Hashida","year":"2012","unstructured":"Hashida N, Ohguro N, Nishida K (2012) Efficacy and complications of intravitreal rituximab injection for treating primary vitreoretinal lymphoma. Transl Vis Sci Technol 1(3):1","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"1805_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/bjophthalmol-2013-304043","volume":"98","author":"KL Larkin","year":"2014","unstructured":"Larkin KL, Saboo US, Comer GM, Forooghian F, Mackensen F, Merrill P, Sen HN, Singh A, Essex RW, Lake S, Lim LL (2014) Use of intravitreal rituximab for treatment of vitreoretinal lymphoma. Br J Ophthalmol 98(1):99\u2013103","journal-title":"Br J Ophthalmol"},{"key":"1805_CR12","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/bjo.72.12.905","volume":"72","author":"DH Char","year":"1988","unstructured":"Char DH, Ljung BM, Deschenes J et al (1988) Intraocular lymphoma: immunological and cytological analysis. Br J Ophthalmol 72:905\u2013911","journal-title":"Br J Ophthalmol"},{"key":"1805_CR13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ajo.2007.03.031","volume":"144","author":"CJ Calfa","year":"2007","unstructured":"Calfa CJ, Lossos IS, Ruiz P, Davis JL (2007) Ocular involvement as the initial manifestation of T-cell chronic lymphocytic leukemia. Am J Ophthalmol 144:326\u2013329","journal-title":"Am J Ophthalmol"},{"key":"1805_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1136\/bjo.2007.130062","volume":"92","author":"KJ Vicuna","year":"2008","unstructured":"Vicuna KJ, Frenkel S, Siegal T et al (2008) Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption. Br J Ophthalmol 92:231\u2013235","journal-title":"Br J Ophthalmol"},{"key":"1805_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/00006982-199515020-00006","volume":"15","author":"S Valluri","year":"1995","unstructured":"Valluri S, Moorthy RS, Khan A, Rao NA (1995) Combination treatment of intraocular lymphoma. Retina 15:125\u2013129","journal-title":"Retina"},{"key":"1805_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s10384-005-0327-4","volume":"50","author":"JK Wang","year":"2006","unstructured":"Wang JK, Yang CM, Lin CP et al (2006) An asian patient with intraocular lymphoma treated by intravitreal methotrexate. Jpn J Ophthalmol 50:474\u2013478","journal-title":"Jpn J Ophthalmol"},{"issue":"11","key":"1805_CR17","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1634\/theoncologist.2011-0210","volume":"16","author":"CC Chan","year":"2011","unstructured":"Chan CC, Rubenstein JL, Coupland SE et al (2011) Primary vitreoretinal lymphoma: a report from an international primary central nervous system lymphoma collaborative group symposium. Oncol 16(11):1589","journal-title":"Oncol"},{"issue":"7","key":"1805_CR18","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/S1470-2045(15)00076-5","volume":"16","author":"K Hoang-Xuan","year":"2015","unstructured":"Hoang-Xuan K, Bessell E, Bromberg J et al (2015) European association for neuro-oncology Task Force on primary CNS lymphoma Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European association for neuro-oncology. Lancet Oncol 16(7):e322\u2013e332","journal-title":"Lancet Oncol"},{"key":"1805_CR19","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1093\/annonc\/mdm340","volume":"18","author":"SA Grimm","year":"2007","unstructured":"Grimm SA, Pulido JS, Jahnke K et al (2007) Primary intraocular lymphoma: an international primary central nervous system lymphoma collaborative group report. Ann Oncol 18:1851\u20131855","journal-title":"Ann Oncol"},{"key":"1805_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jamaophthalmol.2014.4755","volume":"133","author":"A Riemens","year":"2015","unstructured":"Riemens A, Bromberg J, Touitou V et al (2015) Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. JAMA Ophthalmol 133:191\u2013197","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"1805_CR21","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/sj.eye.6702437","volume":"21","author":"A Berenbom","year":"2007","unstructured":"Berenbom A, Davila RM, Lin HS, Harbour JW (2007) Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye 21(9):1198\u20131201","journal-title":"Eye"},{"key":"1805_CR22","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.ijrobp.2011.12.097","volume":"84","author":"M Kaushik","year":"2012","unstructured":"Kaushik M, Pulido JS, Schild SE, Stafford S (2012) Risk of radiation retinopathy in patients with orbital and ocular lymphoma. Int J Radiat Oncol Biol Phys 84:1145\u20131150","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1805_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2141.2010.08321.x","volume":"151","author":"A Stefanovic","year":"2010","unstructured":"Stefanovic A, Davis J, Murray T et al (2010) Treatment of isolated primary intraocular lymphoma with high-dose methotrexate-based chemotherapy and binocular radiation therapy: a single institution experience. Br J Haematol 151:103\u2013106","journal-title":"Br J Haematol"},{"key":"1805_CR24","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/1097-0142(19800215)45:4<688::AID-CNCR2820450412>3.0.CO;2-F","volume":"45","author":"L Margolis","year":"1980","unstructured":"Margolis L, Fraser R, Lichter A et al (1980) The role of radiation therapy in the management of ocular reticulum cell sarcoma. Cancer 45:688\u2013692","journal-title":"Cancer"},{"key":"1805_CR25","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/IAE.0b013e31804ac032","volume":"27","author":"JS Pulido","year":"2007","unstructured":"Pulido JS, Bakri SJ, Valyi-Nagy T, Shukla D (2007) Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control. Retina 27:1071\u20131073","journal-title":"Retina"},{"issue":"10","key":"1805_CR26","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/cas.13012","volume":"107","author":"H Akiyama","year":"2016","unstructured":"Akiyama H, Takase H, Kubo F et al (2016) High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma. Cancer Sci 107(10):1458\u20131464","journal-title":"Cancer Sci"},{"key":"1805_CR27","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.exer.2005.09.018","volume":"82","author":"H Kim","year":"2006","unstructured":"Kim H, Csaky KG, Chan CC et al (2006) The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res 82:760\u2013766","journal-title":"Exp Eye Res"},{"key":"1805_CR28","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","volume":"104","author":"G Cartron","year":"2004","unstructured":"Cartron G, Watier H, Golay J, Solal-Celigny P (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104:2635\u20132642","journal-title":"Blood"},{"issue":"7","key":"1805_CR29","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamaophthalmol.2017.1810","volume":"135","author":"CL Shields","year":"2017","unstructured":"Shields CL, Sioufi K, Mashayekhi A, Shields JA (2017) Intravitreal melphalan for treatment of primary vitreoretinal lymphoma. JAMA Ophthalmol 135(7):815","journal-title":"JAMA Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-01805-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-021-01805-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-01805-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T09:03:30Z","timestamp":1624871010000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-021-01805-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1805"],"URL":"https:\/\/doi.org\/10.1007\/s10792-021-01805-1","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,17]]},"assertion":[{"value":"15 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare that they have no ethical conflicts to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all study participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent obtained from all co-authors for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}